Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice

被引:201
作者
Bolland, S
Yim, YS
Tus, K
Wakeland, EK
Ravetch, JV
机构
[1] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA
[2] Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75235 USA
关键词
lpr; yaa; Sle1; autoantibodies; glomerulonephritis;
D O I
10.1084/jem.20020165
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
FcgammaRIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice deficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis displayed by this gene we have constructed hybrids between FcgammaRIIB(-/-) and the systemic lupus erythematosus (SLE) modifiers yaa and lpr and the susceptibility locus Sle1. Sle1 and B6.RIIB-/- are both physically and functionally coupled; compound heterozygotes of Sle1 and B6.RIIB-/- develop significant disease, while single heterozygotes display no evidence of autoimmunity or disease, indicating that these genes lie on the same genetic pathway resulting in the loss of tolerance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for the severity of autoimmune disease in this model, as demonstrated by analysis of yaa and lpr hybrids. Thus, B6.RIIB-/-/lpr mice are protected from disease progression, despite equivalent titers of ANA. In contrast, B6.RIIB-/-/yaa mice have significantly enhanced disease despite reduced ANA titers. Yaa modifies the specificity and thus the pathogenicity of the B6.RIIB-/- ANA, by converting them to antinucleolar antibodies. In addition to these known modifier pathways, we have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required for the ANA phenotype, further indicating the epistatic properties of this SLE model.
引用
收藏
页码:1167 / 1174
页数:8
相关论文
共 37 条
  • [1] Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
    Bachmaier, K
    Krawczyk, C
    Kozieradzki, I
    Kong, YY
    Sasaki, T
    Oliveira-dos-Santos, A
    Mariathasan, S
    Bouchard, D
    Wakeham, A
    Itie, A
    Le, J
    Ohashi, PS
    Sarosi, I
    Nishina, H
    Lipkowitz, S
    Penninger, JM
    [J]. NATURE, 2000, 403 (6766) : 211 - 216
  • [2] Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis
    Bolland, S
    Ravetch, JV
    [J]. IMMUNITY, 2000, 13 (02) : 277 - 285
  • [3] The role of Fas in autoimmune diabetes
    Chervonsky, AV
    Wang, Y
    Wong, FS
    Visintin, I
    Flavell, RA
    Janeway, CA
    Matis, LA
    [J]. CELL, 1997, 89 (01) : 17 - 24
  • [4] Cbl-b regulates the CD28 dependence of T-cell activation
    Chiang, YPJ
    Kole, HK
    Brown, K
    Naramura, M
    Fukuhara, S
    Hu, RJ
    Jang, IK
    Gutkind, JS
    Shevach, E
    Gu, H
    [J]. NATURE, 2000, 403 (6766) : 216 - 220
  • [5] Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors
    Clynes, R
    Maizes, JS
    Guinamard, R
    Ono, M
    Takai, T
    Ravetch, JV
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) : 179 - 185
  • [6] Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis
    Clynes, R
    Dumitru, C
    Ravetch, JV
    [J]. SCIENCE, 1998, 279 (5353) : 1052 - 1054
  • [7] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    Clynes, RA
    Towers, TL
    Presta, LG
    Ravetch, JV
    [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446
  • [8] GENETIC CONTRIBUTIONS TO LUPUS-LIKE DISEASE IN (NZBXNZW)F-1 MICE
    DRAKE, CG
    ROZZO, SJ
    VYSE, TJ
    PALMER, E
    KOTZIN, BL
    [J]. IMMUNOLOGICAL REVIEWS, 1995, 144 : 51 - 74
  • [9] MULTIPLE DEFECTS IN THE IMMUNE-SYSTEM OF LYN-DEFICIENT MICE, CULMINATING IN AUTOIMMUNE-DISEASE
    HIBBS, ML
    TARLINTON, DM
    ARMES, J
    GRAIL, D
    HODGSON, G
    MAGLITTO, R
    STACKER, SA
    DUNN, ARR
    [J]. CELL, 1995, 83 (02) : 301 - 311
  • [10] Hogarth MB, 1998, J IMMUNOL, V161, P2753